On Wednesday, Chesapeake Energy Corporation (NYSE:CHK)’s shares declined -7.37% to $6.54.
CHK has the market capitalization of $4.70 billion. The stock has P/B ratio of 3.55 while EPS was $-18.55. Institutional ownership of the company was 95.60% while 665.07 million shares were outstanding. Net profit margin of the Company was -87.70% while its gross profit margin was 90.40%. Share of the company moved below its SMA 50 with -16.17%. ROE ratio was -155.50% while ROI was 8.40%.
The mean estimate for the short term price target for Chesapeake Energy Corporation (CHK) stands at $8.57 according to 27 Analysts. The higher price target estimate for the stock has been calculated at $13.00 while the lower price target estimate is at $5.00.
Analysts mean recommendation for the stock is -3.20. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Chesapeake Energy Corporation is a producer of natural gas, oil and natural gas liquids (NGL) in the United States. The Company operates in two segments: Exploration and Production, and Marketing, Gathering and Compression.
Opko Health Inc. (NYSE:OPK)’s shares gained 1.68% to $10.90.
OPK Its past 5-day performance at 15.34% . So far in 2015, the company has a year-to-date performance of 9.11%. The stock, as of last close, traded 34.90% up from its 52 week low and was -43.23% below its 52 week high. Its latest closing price was -19.71% below the SMA200 while the distance from SMA 50 and SMA 20 was 13.33% and 13.82% respectively.
The mean estimate for the short term price target for Opko Health Inc. (OPK) stands at $17.20 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $22.00 while the lower price target estimate is at $11.00.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines.
At the end of Wednesday’s trade, Astoria Financial Corp (NYSE:AF)‘s shares dipped -0.75% to $15.91.
AF has market capitalization of $1.62 billion. Its shares were below its 50 days simple moving average with -3.28%. The company offered earning per share of $0.84 while its 100.79 million shares were outstanding. YTD performance of the company was 19.09%. Stock volatility for the week was 1.91% while for the month it was shown at 2.94%.
The mean estimate for the short term price target for Astoria Financial Corp (AF) stands at $16.68 according to 11 Analysts. The higher price target estimate for the stock has been calculated at $20.00 while the lower price target estimate is at $14.00.
Analysts mean recommendation for the stock is 2.80. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Astoria Financial Corporation is the unitary savings and loan holding company of Astoria Bank and its subsidiaries. The Company’s principal business includes the operation of its wholly owned subsidiary, Astoria Bank. Astoria Bank’s business is attracting retail deposits from the general public and businesses and investing those deposits, together with funds generated from operations, principal repayments on loans and securities and borrowings, in multi-family and commercial real estate mortgage loans, one-to-four family, or residential, mortgage loans, and mortgage-backed securities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.